AI spending isn’t expected to slow in 2026. In a research note shared with TheStreet, Goldman Sachs predicted that ...
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models.
The companies were the latest to agree to sell drugs to Medicaid and directly to consumers at discounted prices. President ...
President Trump told NBC News that he hasn't ruled out war against Venezuela. “I don’t rule it out, no,” Trump told the news ...
Investor's Business Daily on MSN
Why FedEx stock is falling despite earnings surprise and price target hikes
The company remains in cost-cutting mode. On Thursday, FedEx said that its operating results improved in the second quarter, ...
Three stocks that did well during the last big bear market in 2022 are AbbVie ( ABBV +0.15%), Eli Lilly ( LLY +2.09%), and Chevron ( CVX 1.32%). Here's why they could potentially be good investments ...
Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...
Major stock indexes surged Thursday after delayed Consumer Price Index data came in better than expected, with the blue-chip ...
The report estimates that out-of-pocket costs for the 10 drugs will fall nearly 50% in 2026 versus 2025 in all 56 stand-alone prescription drug plans in California, Florida, Texas, New York, and ...
Eli Lilly's stock has beaten Nvidia's this year, and the outperformance has been especially sharp in recent weeks. The recent rotation into healthcare stocks and out of hot technology plays can be ...
Eli Lilly's retatrutide compound mimics three hormones associated with hunger regulation. "Lilly Reports Positive Results in Next-Gen Obesity Drug Trial -- Update," at 8:27 a.m. ET on Dec. 11, ...
Pharmacy benefit managers (PBMs) significantly impact GTN revenue through rebates, but patient access issues persist due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback